On January 12, 2026, Hunan Zhongsheng Peptide Biotechnology Co., Ltd. made a public announcement, revealing that it had entered into a comprehensive global licensing and collaborative agreement with Novartis. This deal pertains to a yet-to-be-disclosed peptide-based asset within the realm of radioligand therapy.

As per the terms of the agreement, Novartis has secured exclusive global rights to this asset. The pharmaceutical giant will take the helm in all subsequent research and development endeavors, as well as spearhead the commercialization efforts. In return for these rights, Zhongsheng Peptide is set to receive an initial payment of $50 million. Moreover, the Chinese biotech firm stands to gain additional payments contingent upon achieving various research and development, regulatory approval, and sales milestones. Additionally, Zhongsheng Peptide retains the right to earn tiered royalties, which will be calculated based on the future global net sales of the asset.